Mansfield AS - Search Results

1

Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer.

Duma N, Idossa DW, Durani U, Frank RD, Paludo J, Westin G, Lou Y, Mansfield AS, Adjei AA, Go RS, Ailawadhi S. Duma N, et al. Among authors: mansfield as. Clin Lung Cancer. 2020 May;21(3):e115-e129. doi: 10.1016/j.cllc.2019.08.005. Epub 2019 Aug 30. Clin Lung Cancer. 2020. PMID: 31570228

2

Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer.

Mansfield AS, Fields AP, Jatoi A, Qi Y, Adjei AA, Erlichman C, Molina JR. Mansfield AS, et al. Anticancer Drugs. 2013 Nov;24(10):1079-83. doi: 10.1097/CAD.0000000000000009. Anticancer Drugs. 2013. PMID: 23962904 Free PMC article. Clinical Trial.

3

Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer.

Kourelis TV, Wysokinska EM, Wang Y, Yang P, Mansfield AS, Tafur AJ. Kourelis TV, et al. Among authors: mansfield as. Lung Cancer. 2014 Dec;86(3):358-62. doi: 10.1016/j.lungcan.2014.10.003. Epub 2014 Oct 12. Lung Cancer. 2014. PMID: 25453848 Free PMC article.

4

Reflections on immune checkpoint inhibition in non-small cell lung cancer.

Leventakos K, Mansfield AS. Leventakos K, et al. Among authors: mansfield as. Transl Lung Cancer Res. 2014 Dec;3(6):411-3. doi: 10.3978/j.issn.2218-6751.2014.09.09. Transl Lung Cancer Res. 2014. PMID: 25806337 Free PMC article. No abstract available.

5

Radiotherapy for extensive stage small-cell lung cancer.

Mansfield A, Mandrekar S. Mansfield A, et al. Lancet. 2015 Apr 4;385(9975):1291. doi: 10.1016/S0140-6736(15)60676-6. Lancet. 2015. PMID: 25890909 No abstract available.

6

Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers.

Xie D, Marks R, Zhang M, Jiang G, Jatoi A, Garces YI, Mansfield A, Molina J, Yang P. Xie D, et al. J Thorac Oncol. 2015 Aug;10(8):1213-20. doi: 10.1097/JTO.0000000000000585. J Thorac Oncol. 2015. PMID: 26200277 Free article.

7

Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.

Mansfield AS, Dong H. Mansfield AS, et al. Clin Pharmacol Ther. 2016 Sep;100(3):220-2. doi: 10.1002/cpt.360. Epub 2016 May 3. Clin Pharmacol Ther. 2016. PMID: 26916808

8

S768I Mutation in EGFR in Patients with Lung Cancer.

Leventakos K, Kipp BR, Rumilla KM, Winters JL, Yi ES, Mansfield AS. Leventakos K, et al. Among authors: mansfield as. J Thorac Oncol. 2016 Oct;11(10):1798-801. doi: 10.1016/j.jtho.2016.05.007. Epub 2016 May 20. J Thorac Oncol. 2016. PMID: 27211795 Free PMC article.

9

Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer.

Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Mansfield AS, et al. J Thromb Haemost. 2016 Sep;14(9):1773-8. doi: 10.1111/jth.13378. Epub 2016 Sep 9. J Thromb Haemost. 2016. PMID: 27273134 Free PMC article.

10

Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.

Leventakos K, Mansfield AS. Leventakos K, et al. Among authors: mansfield as. BioDrugs. 2016 Oct;30(5):397-405. doi: 10.1007/s40259-016-0187-0. BioDrugs. 2016. PMID: 27411930 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

206 results

Search Page

Filters